

R E V I E W

Drug reaction with eosinophilia and systemic symptoms (DRESS) in children

Francesca Mori¹, Carlo Caffarelli², Silvia Caimmi³, Paolo Bottau⁴, Lucia Liotti⁵, Fabrizio Franceschini⁶, Fabio Cardinale⁷, Roberto Bernardini⁸, Giuseppe Crisafulli⁹, Francesca Saretta¹⁰, Elio Novembre¹

¹ Allergy Unit, Department of Pediatric Medicine, Anna Meyer Children's University Hospital, Florence, Italy; ² Clinica Pediatrica, Dipartimento di Medicina e Chirurgia, Azienda Ospedaliero-Universitaria, Università di Parma, Italy; ³ Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy; ⁴ Pediatric and Neonatology Unit, Imola Hospital, Imola (BO), Italy; ⁵ Department of Pediatrics, Senigallia Hospital, Senigallia, Italy; ⁶ UOC Pediatria, Azienda Ospedaliero-Universitaria "Ospedali Riuniti", Ancona, Italy; ⁷ UOC di Pediatria, Azienda Ospedaliero-Universitaria "Consorziale-Policlinico", Ospedale Pediatrico Giovanni XXIII, Bari, Italy; ⁸ Paediatric Unit, "San Giuseppe" Hospital, Empoli, Italy; ⁹ UO Allergologia, Dipartimento di Pediatria, Università di Messina, Italy; ¹⁰ Pediatric Department, AAS2 Bassa Friulana-Isonzia, Palmanova-Latisana, Italy; Pediatric Allergy Unit, Department of Medicine, Udine, Italy

Summary. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a severe reaction to drugs. Incidence of DRESS in children is not well known and the mortality rate seems to be lower than 10%. Anticonvulsants are the main drugs involved both in adults and in children. The treatment of choice is intravenous immunoglobulins and corticosteroids used in synergy. Today there are not controlled clinical trials regarding DRESS treatment in children. Anyway, the prompt withdrawal of the offending drug is of paramount importance for a better prognosis. DRESS sequels may occur, consequently, follow-up visits are required at least until the first year after the reaction. (www.actabiomedica.it)

Key words: children, drug reaction with eosinophilia and systemic symptoms, severe cutaneous adverse reaction

Epidemiology

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a serious and potentially fatal adverse reaction to therapeutic medications. Over the last 80 years, the nomenclature of this disease has been changing from drug-induced pseudolymphoma, anticonvulsant hypersensitivity syndrome, drug induced hypersensitivity syndrome (DIHS), drug induced delayed multiorgan hypersensitivity syndrome to DRESS. DRESS is classified among severe cutaneous adverse reactions (SCARs) and in 1966 Bocquet et al. (1) identified it as a distinct clinical syndrome. Moreover, the meaning of "R" in DRESS acronym has been changed from Rash to Reaction due to the het-

erogeneity of skin eruptions (2). Initially, DRESS was thought to affect only adults, later it was diagnosed also in children (3).

The incidence of DRESS due to antiepileptics is in the range of 1:1000 to 1:10.000 in general population (4) and of 0.4:1000 (5) in hospital settings. In younger children the incidence of DRESS seems to be lower than in adults, although the real incidence is not known (6,7). Anyway, DRESS is more frequent than other severe immediate drug-induced reactions such as anaphylaxis (8), or exercise-induced anaphylaxis (9) but less common than food-induced anaphylaxis (10,11). The overall mortality rate is of 10% with a lower percentage in children than in adults (12-13).

Pathogenesis

DRESS is the result of a complex interplay of genetic factors [ethnic predisposition in people with certain human leucocyte antigen (HLA) alleles], immunological response, abnormalities in metabolic pathways (such as a deficiency or abnormality in epoxide hydroxylase, an enzyme that detoxifies the metabolites of aromatic amine anticonvulsants) and associated re-activations of herpes virus family members (HHV-6 and HHV-7, EBV and CMV) (14). In this context, African Americans are most likely to develop DRESS syndrome after initiation of aromatic anticonvulsants drugs whereas the Han Chinese are most likely to develop DRESS after allopurinol intake (15).

In fact, it has been found that DRESS syndrome is associated with certain human leukocyte antigens (HLAs), such as, HLA A*31:01 (aromatic anticonvulsant-induced DRESS); HLA A* 24:02 (lamotrigine-induced DRESS); HLA B*51:01, HLA B*15:13 and CYP2C9*3 (phenytoin-induced DRESS); HLA-B*57:01 and DRB1*01:01 and HLAB*35:05 (abacavir-induced DRESS) and HLA-B*58:01 (allopurinol-induced DRESS); HLA C*04:01 (nevirapine-induced DRESS) (16-19).

Apart from HLA, cytochrome P4502C9 marker has been reported to be involved in phenytoin induced SCARs (20-21).

Moreover, being a slow acetylator of drugs is thought to be a risk factor for DRESS syndrome (22).

Drugs may act as foreign antigens, binding to HLA/peptide/TCR complex and inducing hypersensitivity reactions. DRESS is a delayed type reaction according to Gell and Coombs classification (23).

There are four hypotheses regarding drug presentation mechanisms that have been suggested to explain how small drug molecules might interplay with HLA and TCR in drug hypersensitivity: (1) the hapten theory, (2) the pharmacological interaction with immune receptors (p-i) concept (i.e. carbamazepine directly interacts with HAL B*15:02) (3) the altered peptide repertoire model (i.e. abacavir binds to the F-pocket of HLA B*57:01), and (4) the altered TCR repertoire model (i.e. sulfamethoxazole directly interacts with TCR).

In delayed type reactions such as DRESS syndrome, drug antigens may activate specific T lympho-

cytes or natural killer cells with production of various cytokines/chemokines (i.e. TNF- α , IFN- γ , IL-2, IL-4, IL-5, TARC/CCL17, IL-6, IL-15, and IL-13) (16).

Furthermore, viruses have also been proposed to be involved in HLA/drug/TCR interactions and play an important role in drug hypersensitivity reactions, representing a source of exogenous peptides for drug presentation (24).

So far, the role of viruses in the pathogenesis of DRESS is unclear: a) Viral reactivation may be provoked by a cytokine storm secondary to an immune response against the drug (25); b) DRESS is a consequence of a strong immune response against an early viral reactivation (26). CD4+ and CD8+ drug-specific T cells proliferate after encountering the drug, but also anti-viral specific T cell can be cross-activated by drugs. In conclusion, the most common hypothesis is that the immunologic response to drugs induces a boost viral reactivation, consequently T lymphocytes and monocytes/macrophages release viruses that represents as an early marker of stimulation of these cells, rather than the triggering event in the pathogenesis of DRESS (27). In particular, toxic drug metabolites accumulation provoke an immunosuppression of B cells with hypogammaglobulinemia and subsequent viral re-activation (28). For example, in Asia and Europe the detection of HHV-6 copies in DRESS cases has been commonly reported with a frequency of 70-80%, making this data as an available diagnostic test (29, 30).

Clinical manifestations

The time onset of DRESS symptoms ranges from 2-6 weeks after initiation of treatment (2), anyway latency periods up to 105 days have been described (31).

Retrospective studies have found that the average age of occurrence of DRESS syndrome is 9 years of age in children (7,13). The most common clinical feature is fever, which is usually high grade ranging from 38-40°C. The second most common feature is macular erythema. This kind of rash later evolves in more violaceous and papular lesions with or without pruritus (Figure 1), and over time, the eruption becomes potentially exfoliative. Consequently, although



Figure 1. Acute Rash in DRESS syndrome

a maculopapular rash is the most common initial cutaneous manifestation other eruptions may be described, including targetoid, urticarial, pustular, blistering, lichenoid, exfoliative, and eczematous lesions. The skin eruption typically begins on the face associated to facial oedema and then involves the upper trunk progressively spreading at lower extremities. The skin can be involved from less than 50% of body surface to diffuse erythroderma, making consistent the cutaneous distribution of the eruption. Moreover, mucosal involvement has been frequently (>50%) described (i.e. conjunctivitis, oral mucositis and/or genital lesions) in DRESS (7).

The eruption can persist for months after the offending drug has been discontinued. Lymphadenopathy is the third most common presentation, which is seen in 70-75% of patients (32).

Haematological abnormalities, such as leucocytosis, eosinophilia, atypical lymphocytosis, thrombocytopenia and agranulocytosis commonly occur in DRESS.

Eosinophilia is typically reported in DRESS studies from both Asia and Europe with percentages ranging from 48 to 95% of patients (2, 7, 33).

Among visceral organ, liver (i.e. hepatitis) is involved in 50-80% of patients, followed by kidney (i.e. nephritis with haematuria or acute renal failure) in 11-28% of patients. Unfortunately, in some patients, hepatic injury can progress to widespread hepatic necrosis and fulminant liver failure (29, 34, 35) and it represents the leading cause of mortality in these patients (36).

Lungs (i.e. pneumonitis) are involved in 2.6-5% patients, but also muscle (myositis), gastrointestinal (i.e. colitis) heart (i.e. myocarditis), pancreas (i.e. pancreatitis), brain (i.e. encephalitis), thyroid (i.e. thyroiditis) and conjunctiva (i.e. conjunctivitis) involvements have been described (31-37). In table 1 are reported the clinical features of DRESS syndrome (29, 35, 36, 38-44). Clinical manifestations were similar between children and adults, with the exception of pulmonary involvement (excluding asthma), which was more

Table 1. Most common clinical features of DRESS syndrome and percentages of organ involvement

Fever (>38°C)	86.5%	(38)
Acute Rash	85%	(38)
Facial Swelling with periorbital involvement	27%	(38)
Lymphadenopathy	70%	(38)
Eosinophilia	60-80%	(29, 30, 38)
Liver: Hepatomegaly and/or increase liver enzymes (AST/ALT) and/or hyperbilirubinemia; elevated Alkaline phosphatase (30)	51-84%	(35, 36, 40-41)
Kidney: Elevation in creatinine Decrease in glomerular filtration rate (GFR) Proteinuria Haematuria *Allopurinol is most commonly implicated with renal involvement (36)	11-57%	(35, 40-41)
Lungs: Interstitial pneumonitis Pneumonia Pleural effusion Acute respiratory distress Syndrome (ARDS) *Minocycline, Allopurinol, Abacavir are most commonly implicated with lung involvement (26, 37)	2.6-5%	(29, 36)
Non specific Gastrointestinal Symptoms: Colitis Diarrhoea with or without electrolyte abnormalities	8%	(35, 42)
Heart: Late onset Myocarditis (Troponin and CKMB elevated) Tachycardia, arrhythmias, chest pain, non specific ECG changes, gross ST segment, elevation or depression, decrease in LV ejection fraction * Ampicillin is most commonly implicated with heart involvement	4-27%	(43,44)

frequent in adults, and gastrointestinal involvement, which was more frequent in children (42).

Drugs Involved

More than 40 medications have been described as triggers of DRESS and among various drugs, aromatic antiepileptics are reported to be the most common cause followed by antibiotics. Moreover, aromatic anticonvulsants show cross-reactivity in 40-80% of cases while non aromatic anticonvulsants are well tolerated as alter-

native choice in case of reactions to aromatics. Anyway, data about DRESS in children are scarce and mostly come from case reports. In the study of Misirlioglu et al (45), antibiotics were the most common (50%) medication in the aetiology; 87.5% of the suspected antibiotics were beta-lactams, and 12.5% were macrolides. Antiepileptics were second (37.5%, n. 6) most common class of drugs in the aetiology. In Table 2 we reported the drugs most frequently involved in DRESS syndrome in children in the last ten years. Studies where children were included but not clearly specified in terms of age and culprit drugs, were excluded.

Table 2. Most frequently reported drugs causing DRESS syndrome in children

Single case or less than 10 children (mean age 7,6 years) (46-114)	<ul style="list-style-type: none"> • carbamazepine 14/103 (13.6%) • phenytoin 12/103 (11.7%) • phenobarbital 9/103 (8.8%) • valproic acid 6/103 (5.9%) • vancomycin 5/103 (5%) • lamotrigine 4/103 (4%) • cefotaxime 4/103 (4%) • trimethoprim-sulfamethoxazole 4/103 (4%) • ceftriaxone 3/103 (3%) • levetiracetam 3/103 (3%) • dapsone 3/103 (3%) • clindamycin 2/103 (2%) • piperacillin-tazobactam 2/103 (2%) • azithromycin 2/103 (2%) • oxacarbamazepine 2/103 (2%) • minocycline 2/103 (2%) • sulfadiazine 2/103 (2%) • oxacilline 2/103 (2%) • penicillin 2/103 (2%) • cefixime 1/103 (0.9%) • naproxen 1/103 (0.9%) • canakinumab 1/103 (0.9%) • amoxi-clav 1/103 (0.9%) • anakinra 1/103 (0.9%) • tobramycin 1/103 (0.9%) • ibuprofen 1/103 (0.9%) • acetylsalicylic acid 1/103 (0.9%) • griseofulvine 1/103 (0.9%) • sulthiame 1/103 (0.9%) • infliximab 1/103 (0.9%) • fluoxetina 1/103 (0.9%) • cefepime 1/103 (0.9%) • allopurinol 1/103 (0.9%) • perampanel 1/103 (0.9%) • cefditoren-pivoxil 1/103 (0.9%) • paracetamol 1/103 (0.9%) • Ethambutol+rifampin+pyranzinamide 1/103 (0.9%) • pyrimethamine 1/103 (0.9%) • rufinamide 1/103 (0.9%)
32 children (mean age 8,9 y) (13)	<ul style="list-style-type: none"> • 13 carbamazepine • 12 phenytoin • 5 phenobarbital • 5 lamotrigine • 1 primidone • 1 oxcarbamazepine
33 children (mean age 5,8 y) (115)	<ul style="list-style-type: none"> • 18 phenobarbital • 15 phenytoin

(continued)

Table 2 (continued). Most frequently reported drugs causing DRESS syndrome in children

29 children (mean age 11 y) (116)	<ul style="list-style-type: none"> • 10 trimethoprim-sulfamethoxazole • 3 phenytoin • 3 amoxicillin • 2 cefalosporins • 2 lamotrigine • 2 minocyclin • 2 macrolids • 2 oxcarbamazepine • 1 carbamazepine • 1 clindamycin • 1 zonisamide
11 children (mean age 6,6 y) (117)	<ul style="list-style-type: none"> • 4 lamotrigine • 1 cefotaxime • 2 carbamazepine • 1 phenytoin + phenobarbital • 3 amoxi-clav
16 children (mean age 8,2 y) (45)	<ul style="list-style-type: none"> • 3 amoxi-clav • 1 ampicillin-sulbactam • 2 cefdinir • 1 cefotaxime • 1 clarythromycin • 3 carbamazepine • 1 lamotrigine • 1 phenytoin • 1 phenobarbital • 1 sulfasalazine • 1 oxymetazoline nasal spray

Diagnosis

Due to the variability of its presentation, DRESS is known as “the great mimicker” making difficult the diagnosis (118). In particular, DRESS symptoms resemble those of cutaneous and systemic infectious diseases and can appear up to 3 months after the initial culprit drug exposure. The allergy work-up should start with a detailed record of clinical history by focusing on the chronology of drug assumptions and physical examination. Laboratory testing is fundamental, it should include liver, and kidney functions, search for viral infections, complete blood count and coagulation testing.

There are no clear and specific histopathological patterns in skin biopsy that are characteristic of DRESS Syndrome. Maculopapular exanthema (MPE) may be

the initial presentation of SCARs including DRESS (119-120). When comparing DRESS with MPE, skin biopsies showed differences in terms of inflammatory infiltrate, atypical lymphocytes, keratinocyte damage, dermal involvement and leukocytoclastic vasculitis, these characteristics being more frequently observed in DRESS cases than in MPE cases (86, 121). Few necrotic keratinocytes were associated with non-severe DRESS cases, otherwise high amount of necrotic keratinocytes with confluent necrotic areas were associated with severe DRESS, respectively. Anyway, the role of skin or lymph node biopsies remains controversial (119).

Eosinophilia is a diagnostic criterion for DRESS. In physiologic conditions, eosinophils are not present in skin, liver, lungs or other internal organs otherwise in DRESS, eosinophils are typically increased in blood, in skin and in involved organs. Eosinophils infiltrate

organs in response to cytokines and chemokines including eotaxin-1, TARC, IL-5 and granule release representing key factors of tissue damage (122).

The discovery of biomarkers of drug hypersensitivity could be useful for the diagnosis of DRESS syndrome. In DRESS cases, serum TARC levels have been reported to be significantly higher than those in patients with Steven-Johnson Syndrome (SJS)/Toxic epidermal necrolysis (TEN) and MPE during the acute phase and to be correlated with skin eruptions (122). For this reason, TARC could be considered a potential biomarker for the early phase and disease activity of DRESS syndrome.

Re-challenging with the offending drug has been considered the gold standard to diagnose drug eruptions, but in suspected DRESS cases, it should not be used because of the life-threatening nature of this syndrome (2, 123). Patch tests can be useful to prove a drug-specific immune response in DRESS syndrome (124). On the contrary, patch tests to different allergens such as foods have a low diagnostic accuracy (125). In vivo patch tests represent a low-risk method for reproducing delayed hypersensitivity by re-exposing patients to low amount of suspected offending drugs. Anyway, the sensitivity and specificity of patch tests are different according to the drug tested.

The lymphocyte transformation/activation test (LTT/LAT) measures the proliferation of T cells to a drug (126, 127). Unfortunately, it is not standardized for many medications and it is difficult to perform. Furthermore, it usually yields a negative result early in the course of the syndrome, and lacks sensitivity. A positive LTT/LAT is useful to confirm the diagnosis due to very low false positive results (only 2%), however a negative test cannot exclude the diagnosis (128). All these factors prevent widespread use of this test.

For the diagnosis of DRESS syndrome different criteria can be used such as Bocquet's criteria (1), The European Registry of Severe Cutaneous Adverse Reactions to Drugs and Collection of Biological Samples (RegiSCAR) criteria (7) and the Japanese group of Severe Cutaneous Adverse Reactions to Drugs (SCAR-J) criteria (Table 3). The RegiSCAR is most often used to diagnose DRESS (129), it is based on seven independent parameters and three of them are required for the diagnosis of DRESS. According to

RegiSCAR, the diagnosis of DRESS can be definite (score >5), probable (score 4-5), possible (score 2-3) and no (score <2) DRESS syndrome.

Differential Diagnosis

DRESS should be differentiated from viral exanthemas especially EBV infectious mononucleosis, staphylococcal and streptococcal shock syndrome, meningococemia, non infectious drug eruptions (e.g. SJS/TEN), autoimmune diseases (e.g. hypereosinophilic syndrome, Kawasaki disease, Stills diseases), urticaria vasculitis (130), neoplastic diseases (e.g. leukemia cutis, pseudolymphoma, mycosis fungoides), serum sickness like reaction, and atopic erythrodermia. In the last, for example, nephritis and hepatitis are lacking, being caused by bacterial infections (131).

Depending on organs involved, the differential diagnosis also includes viral hepatitis (liver), parasitic infection (gastrointestinal tract) and bacterial, viral and fungal pathogens (lung) (36).

Treatment

So far, there have been no prospective clinical trials on treatment of DRESS syndrome. Current recommendations are based on case reports and expert opinion (132). The first and most important step in treatment of DRESS is withdrawal of the causative drug, because a better prognosis is associated with an earlier discontinuation of the drug.

In mild forms, treatment is mainly supportive and symptomatic, consisting of topical steroids, systemic anti-H1 antihistamines and emollients for rash and itching. In patients with exfoliative dermatitis a prompt and appropriate fluid, electrolyte and nutritional support is of primary importance. In moderate cases without visceral involvement, corticosteroids are usually adequate (133).

In case of organ involvement, such as liver (transaminases >5 times upper limit of normal), kidney, lungs or heart, the expert opinion of French Society of Dermatology recommended to administer corticosteroid (prednisone, 1 mg/kg/day per os). Several aspects

Table 3. Three proposed diagnostic criteria of DRESS syndrome

	Bocquet et al. (1)	RegiSCAR (7)	J-SCAR (129)
Requirement for diagnosis	≥3 criteria	≥3 criteria of the following asterisk marks	all 7 criteria = typical without 2 asterisk marks = atypical
History		- hospitalization - reaction suspected to be drug related	- symptoms persisting at least 2 weeks after drug discontinuation
Fever		- fever ≥38°C*	- fever ≥38°C
Cutaneous finding	- acute drug eruption	- acute rash	- macular rash developing 3 weeks after starting offending drug
Hematologic abnormalities	- eosinophilia >1.5×10 ⁹ /L or atypical lymphocytosis	one of the following hematologic abnormalities - eosinophilia over laboratory limits - lymphocyte count over and under normal limits - thrombocytopenia under laboratory limits	one of the following hematologic abnormalities - leucocytosis (>11×10 ⁹ /L) - atypical lymphocytes (>5%) - eosinophilia (>1.5×10 ⁹ /L)
Other organ involvements	- lymphadenopathy ≥2 cm in diameter - hepatitis with liver transaminases ≥2 times of the normal values - interstitial nephritis - interstitial pneumonitis - carditis	- lymphadenopathy involving ≥2 sites* - at least 1 internal organ involvement*	- lymphadenopathy* - liver abnormalities (ALT >100 U/L)
Viral reactivation			- HHV-6 reactivation*

(i.e. optimal dose, route of administration, duration of treatment, and rapidity of dose tapering) of steroid treatment have not been compared in controlled trials (119). Tapering should take three to six months of time because rapid taper can be associated with relapse of DRESS (119, 134, 135). Systemic steroid therapy is advised to treat cases of moderate to severe disease taking into account the dramatic improvement in symptoms and frequent relapses of DRESS associated with quick prednisone taper. For all these reasons, intravenous pulses of methylprednisolone (1 g/d) are recommended especially in patients worsening despite adequate doses of oral corticosteroids (52).

Proposed mechanism by which corticosteroids benefit the patient is inhibition of IL-5, which attracts eosinophils, which are responsible for visceral organ

damage by accumulation in DRESS syndrome (35). For the same reason, some authors proposed the use of mepolizumab (anti IL-5) in the treatment of DRESS (136).

Today, cyclosporine may be considered a second-line therapy for patients with severe organ involvement who do not respond to systemic corticosteroids and for patients in whom corticosteroids are contraindicated (137). Intravenous immunoglobulins (IVIG) have been reported to be useful in a few patients with DRESS and detrimental in others (138). Periodical controls (both clinical and laboratory parameters) are necessary to check progression of the skin eruption and/or development of clinical fatal life-threatening signs, which include hemophagocytosis with bone marrow failure, encephalitis, severe hepatitis, renal

failure, and respiratory failure requiring treatment with steroids generally administered at a dose of 2 g/kg over 5 days with IVIG. The largest series of paediatric patients have been described by Marcu N et al. (62) who reported 7 patients with severe DRESS in whom treatment with IVIG (1-2 gr/kg) in addition to systemic corticosteroids was successful. One possible explanation is that IVIG preparations contain anti-viral neutralizing antibodies that help clear the viral infection/reactivation found to be fundamental in the pathophysiology of DRESS. Anyway, IVIG should not be administered in the absence of steroids.

Due to the fact that there is a major viral reactivation along with presence of life-threatening signs, it has been proposed to administer anti-viral medications (e.g. ganciclovir) in combination with steroids with or without IVIG but the efficacy is unclear (139).

In severe and corticosteroid-resistant cases, more potent immunosuppressant medications including cyclosporine, azathioprine, rituximab, infliximab and mycophenolate have been used, sometimes alongside adjunctive treatment with IVIG and plasmapheresis (42, 66, 140, 141). N-acetyl cysteine (NAC), which acts as detoxifying drug, can also be used in DRESS.

Finally, the treatment of DRESS syndrome should be started immediately after diagnosis, even if the result of viral markers are still ongoing. Further studies with appropriate designs (i.e. randomized controlled trials) are needed to establish a standard of care in DRESS. Such studies should also assess the potential application of anti-viral drugs or probiotics for treating infections (142, 143, 144).

Prognosis

After withdrawal of the causative drug, most of the patients need some weeks to completely recover. The prevalence of sequelae is unknown. Long-term sequelae may be renal failure, chronic anaemia, autoimmune diseases (autoimmune thyroid disease, diabetes mellitus type I, systemic lupus erythematosus (SLE), systemic sclerosis, adrenal insufficiency and autoimmune haemolytic anaemia). For example, thyroiditis has been reported in the 12.5% of children with a previous DRESS (7).

Moreover, recurrence of DRESS with unrelated drugs can be observed in 25% of cases, whereas very little or no flares are reported in patients after SJS/TEN (145, 146).

Those manifestations can occur months to years following the initial episode and awareness of association with a drug administration is crucial to promptly recognise and treat a possible DRESS. Follow-up visits at 2, 3, 4, 5, 6, 12 months and then once a year are recommended (146, 148).

Conflict of interest: None to declare

References

1. Bocquet H, Bogot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). *Semin Cutan Med Surg* 1996; 15: 250-57.
2. Choudhary S, McLeod M, Torchia D, Romanelli P. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome. *J Clin Aesthet Dermatol* 2013; 6: 31-7.
3. Kani Y, Shiohara T. The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. *Immunol Allergy Clin North Am* 2009; 29:481-501.
4. Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. *Allergol Select* 2017; 4: 1: 96-108.
5. Fiszzenon-Abala F, Auzeur V, Mahe E, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. *Br J Dermatol* 2003;149: 1018-22.
6. Chang DKM, Shear NH (1992) Cutaneous reaction to antiepileptics. *Semin Neurol* 12:329-337.
7. Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. *Br J Dermatol* 2013; 169: 1071-80.
8. Caimmi S, Caimmi D, Bernardini R, et al. Perioperative anaphylaxis: epidemiology. *Int J Immunopathol Pharmacol* 2011; 24(3 Suppl): S21-6.
9. Povesi Dascola C, Caffarelli C. Exercise-induced anaphylaxis: A clinical view. *Ital J Pediatr* 2012; 38: 43.
10. Vetander M, Protudjer JLP, Lilja G, et al. Anaphylaxis to foods in a population of adolescents: incidence, characteristics and associated risks. *Clin Exp Allergy* 2016; 46: 1575-87.
11. Caffarelli C, Ricò S, Rinaldi L, Povesi Dascola C, Terzi C, Bernasconi S. Blood pressure monitoring in children undergoing food challenge: association with anaphylaxis. *Ann Allergy Asthma Immunol* 2012; 108: 285-6.
12. Carroll M, Yueng-Yue K, Esterly N, Drolet BA. Drug-Induced hypersensitivity syndrome in pediatric patients. *Pediatrics* 2001; 108: 485-92.

13. Newell B, Moïnfar M, Mancini A, Nopper A. Retrospective analysis of 32 pediatric patients with anticonvulsant hypersensitivity syndrome (ACHSS). *Pediatr Dermatol* 2009; 26: 536-46.
14. Descamps V. Human herpesvirus 6 involvement in paediatric drug hypersensitivity syndrome. *Br J Dermatol* 2015; 172: 858-59.
15. Chiu M, Hu M, Ng M, et al. Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. *Br J Dermatol* 2012; 167: 44-9.
16. Chen CB, Abe R, Pan RY, et al. An updated review of the molecular mechanisms in drug hypersensitivity. *J Immunol Res* 2018;13: 6431694.
17. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. *Pharmacogenet Genomics* 2006; 16: 297-306.
18. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. *Nature* 2004; 428: 486.
19. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. *N Engl J Med* 2008; 358:568-79.
20. Tassaneeyakul W, Prabmechai N, Sukasem C, et al. Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. *Pharmacogenet Genomics* 2016; 26: 225-34.
21. Suvichapanich S, Jittikoon J, Wichukchinda N, et al. Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children. *J Hum Genet* 2015; 60: 413-17.
22. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. *Clin Pharmacol Ther* 1991; 49: 13-7.
23. Pichler WJ. Delayed drug hypersensitivity reactions. *Ann Intern Med* 2003; 139: 683-93.
24. White KD, Chung WH, Hung SI, Mallal S, Phillips EJ. Evolving models of the immunopathogenesis of T cell-mediated drug allergy: the role of host, pathogens, and drug response. *J Allergy Clin Immunol* 2015; 136: 219-34.
25. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. *Allergol Int* 2006; 55:1-8.
26. Picard D, Janela B, Descamps V, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. *Sci Transl Med* 2010; 2: 46-62.
27. Roujeau J-C, Dupin N. Virus Reactivation in Drug Reaction with Eosinophilia and Systemic Symptoms (Dress) Results from a strong drug-specific immune response. *J Allergy Clin Immunol Pract* 2017; 5: 811-12.
28. Yazicioglu M, Elmas R, Turgut B, Genchallac T. The association between DRESS and the diminished numbers of peripheral B lymphocytes and natural killer cells: Peripheral B lymphocytes and NK cells in DRESS. *Pediatr Allergy Immunol* 2012; 23: 289-96.
29. Cacoub P, Musette P, Descamps V et al. The DRESS syndrome: a literature review. *Am J Med* 2011; 124: 588-97.
30. Shiohara T, Kano Y. A complex interaction between drug allergy and viral infection. *Clin Rev Allergy Immunol* 2007; 33: 124-33.
31. Um SJ, Lee SK, Kim YH, et al. Clinical features of drug induced hypersensitivity syndrome in 38 patients. *J Investig Allergol Clin Immunol* 2010; 20: 556-62.
32. Peyriere H, Dereure O, Breton H, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? *Br J Dermatol* 2006; 155: 422-28.
33. Wongkitisophon P, Chanprapaph K, Rattanakaemakorn P, Vachiramon V. Sixyear retrospective review of drug reaction with eosinophilia and systemic symptoms. *Acta Derm Venereol* 2012; 92: 200e5.
34. Lee JY, Lee SY, Hahm JE, Ha JW, Kim CW, Kim SS. Clinical features of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a study of 25 patients in Korea. *Int J Dermatol* 2017; 56: 944-51.
35. Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. *Arch Dermatol* 2010; 146: 1373-9.
36. Velasco M, McDermott J. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome and hepatitis induced by phenytoin: DRESS syndrome and hepatitis induced by phenytoin. *Int J Dermatol* 2014; 53: 490-93.
37. Behera SK, Das S, Xavier AS, Selvarajan S. DRESS syndrome: a detailed insight. *Hosp Pract (1995)* 2018; 46: 152-62.
38. Wang L, Mei XL. Drug Reaction with Eosinophilia and Systemic Symptoms: Retrospective analysis of 104 cases over one decade. *Chin Med J (Engl)* 2017; 130: 943-9.
39. Hiransuthikul A, Rattananupong T, Klaewsongkram J, Rerknimitr P, Pongprutthipan M, Ruxruntham K. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS): 11 years retrospective study in Thailand. *Allergol Int* 2016; 65: 432-38.
40. Wei CH, R. Chung-Yee Hui R, Chang CJ, et al.. Identifying prognostic factors for drug rash with eosinophilia and systemic symptoms (DRESS). *Eur J Dermatol* 2011; 21: 930-7.
41. Roujeau JC and Stern RS. Severe adverse cutaneous reactions to drugs. *N Engl J Med* 1994; 331: 1272-85.
42. Williams KW, Ware J, Abiodun A, Holland-Thomas NC, Khoury P, Klion AD. Hypereosinophilia in children and adults: a retrospective comparison. *J Allergy Clin Immunol Pract* 2016 ;4: 941-7.
43. Bourgeois GP, Cafardi JA, Groysman V, Hughey LC. A review of DRESS-associated myocarditis. *J Am Acad Dermatol* 2012; 66: e229-36.
44. Thongsri T, Chularojanamontri L, Pichler WJ. Cardiac involvement in DRESS syndrome. *Asian Pacific J Allergy Immunol* 2017; 35: 3-10.

45. Misirlioglu DE, Guvenir H, Bahceci S. Severe cutaneous adverse drug reactions in pediatric patients: a multicenter study. *J Allergy Clin Immunol Pract* 2017; 5: 757-63.
46. Belver MT, Michavila A, Bobolea I, Feito M, Bellón T, Quirce S. Severe delayed skin reactions related to drugs in the paediatric age group: A review of the subject by way of three cases (Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS). *Allergol Immunopathol (Madr)* 2016; 44: 83-95.
47. Silva-Feistner M, Ortiz E, Rojas-Lechuga MJ, Muñoz D. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in pediatrics. Clinical case. *Rev Chil Pediatr* 2017; 88: 158-63.
48. Tonekaboni SH, Jafari N, Chavoshzadeh Z, Shamsian BS, Rezaei N. DRESS Syndrome Presents as Leukoencephalopathy. *Turk J Pediatr* 2015; 57: 541-4.
49. Walsh S, Diaz-Cano S, Higgins E et al. Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases. *Br J Dermatol* 2013; 168: 391-401.
50. Polivka L, Diana JS, Soria A et al. Probable DRESS syndrome induced by IL-1 inhibitors. *Orphanet J Rare Dis* 2017; 12: 87.
51. Castellazzi ML, Esposito S, Claut LE, Daccò V, Colombo C. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in two young children: the importance of an early diagnosis. *Ital J Pediatr* 2018; 44: 93.
52. Koca T, Akcam M. Ibuprofen induced DRESS syndrome in a child. *Indian Pediatr* 2016; 53:745.
53. Kocaoglu C, Cilasun C, Solak ES, Kurtipek GS, Arslan S. Successful Treatment of Antiepileptic Drug-Induced DRESS Syndrome with Pulse Methylprednisolone. *Case Rep Pediatr* 2013; 2013:928910.
54. Terlemez S, Demir F, Bulut Y et al. DRESS syndrome developed related to acetylsalicylic acid use. *Pediatr Allergy Immunol* 2016; 27: 227-30.
55. Smith RJ, Boos MD, McMahon P. Probable griseofulvin-induced drug reaction with eosinophilia and systemic symptoms in a child. *Pediatr Dermatol* 2016; 33: e290-1.
56. Fong CY, Hashim N, Gan CS, Chow TK, Tay CG. Sulthiame-induced drug reaction with eosinophiliavand systemic symptoms (DRESS) syndrome. *Eur J Paediatr Neurol* 2016; 20: 957-61.
57. Karakayalı B, Yazar AS, Çakir D et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome associated with cefotaxime and clindamycin use in a 6 year-old boy: a case report. *Pan Afr Med J* 2017; 28: 218.
58. Chow ML, Kim D, Kamath S, Peng D, Luu M. Use of antiviral medications in drug reaction with eosinophilia and systemic symptoms (DRESS): A case of infantile DRESS. *Pediatr Dermatol* 2018; 35: e114-e116.
59. Dursun A, Bayram AK, Tekerek NÜ, Akyıldız BN, Per H. A case of DRESS syndrome associated with carbamazepine treatment. *Turk Pediatr Ars* 2018; 53: 48-50.
60. Bayram AK, Canpolat M, Çınar SL. Drug reaction with eosinophilia and systemic symptoms syndrome induced by levetiracetam in a pediatric patient. *J Emerg Med* 2016; 50: e61-6.
61. Pereira-Ospina RDP, Bejarano-Quintero AM, Suescún-Vargas JM, Pinzón-Salamanca JY. Drug reaction with eosinophilia and systemic symptoms due to carbamazepine. Pediatric case. *Arch Argent Pediatr* 2018; 116: e433-e436.
62. Anil H, Harmanci K, Tekin RT, Kocak A. Presence of a single nucleotide polymorphism (RS3758581) in a boy with DRESS syndrome. *Cent Eur J Immunol* 2017; 42: 409-11.
63. Marcus N, Smuel K, Almog M, et al. Successful Intravenous Immunoglobulin Treatment in Pediatric Severe DRESS Syndrome. *J Allergy Clin Immunol Pract* 2018; 6: 1238-42.
64. Song SM, Cho MS, Oh SH, et al. Liver transplantation in a child with acute liver failure resulting from drug rash with eosinophilia and systemic symptoms syndrome. *Korean J Pediatr* 2013; 56: 224-6.
65. Lin YC, Sheu JN, Chung WH, et al. Vancomycin-Induced Stevens- Johnson Syndrome in a boy under 2 years old: an early diagnosis by Granulysin Rapid Test. *Front Pediatr* 2018; 6: 26.
66. Kim H, Chadwick L, Alzaidi Y, Picker J, Poduri A, Manzi S. HLA-A*31:01 and Oxcarbazepine-Induced DRESS in a patient with seizures and complete DCX deletion. *Pediatrics* 2018; 141: S434-S438.
67. Chua GT, Rosa Duque JS, Chong PCY, Lee PPW, Lau YL, Ho MHK. Paediatric case series of drug reaction with eosinophilia and systemic symptoms (DRESS): 12-year experience at a single referral centre in Hong Kong and the first reported use of infliximab. *Eur Ann Allergy Clin Immunol* 2018; 50: 273-76.
68. Goswami JN, Vaidya PC, Saini AG, De D, Radotra BD, Singhi PD. Drug reaction with eosinophilia and systemic symptoms in a child on multiple antiepileptics. *Turk J Pediatr* 2017; 59: 197-99.
69. Vignesh P, Kishore J, Kumar A et al. A young child with eosinophilia, rash, and multisystem illness: Drug Rash, Eosinophilia, and Systemic Symptoms Syndrome after receipt of fluoxetine. *Pediatr Dermatol* 2017; 34: e120-e125.
70. Mattoussi N, Ben Mansour A, Essadam L, Guedri R, Fitouri Z, Ben Becher S. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome in children: a case report. *J Investig Allergol Clin Immunol* 2017; 27: 144-6.
71. Vinson AE, Dufort EM, Willis MD, Ebersson CP, Harwell JI. Drug rash, eosinophilia, and systemic symptoms syndrome: Two pediatric cases demonstrating the range of severity in presentation-A case of vancomycin-induced drug hypersensitivity mimicking toxic shock syndrome and a milder case induced by minocycline. *Pediatr Crit Care Med* 2010; 11: e38-43.
72. Irga N, Kosiak W, Jaworski R, Zielinski J, Adamkiewicz-Drozynska E. Pediatrician! Do you know the symptoms of DRESS Syndrome? *Pediatr Emerg Care* 2013; 29: 504-7.
73. Silva-Feistner M, Ortiz E, Rojas-Lechuga MJ, Muñoz D. DRESS syndrome in paediatrics: clinical case. *Rev Chil Pediatr* 2017; 88: 158-63.

74. Coughlin CC, Jen MV, Boos MD. Drug Hypersensitivity Syndrome with prolonged course complicated by parvovirus infection. *Pediatr Dermatol* 2016; 33: e364-e365.
75. Kang H, Min TK, Yang HJ, Pyun BY. Cefotaxime-induced drug rash with eosinophilia and systemic symptoms syndrome in a 7-year-old boy. *Ann Allergy Asthma Immunol* 2016; 117: 202-4.
76. Lan J, Lahoti A, Lew DB. A severe case of minocycline-induced DRESS resulting in liver transplantation and autoimmune sequelae. *Ann Allergy Asthma Immunol* 2016; 116: 367-8.
77. Rueda-Valencia Mde L, Infante S, Campos M, Beléndez C, Saavedra Lozano J. Trimethoprim-sulfamethoxazole induced DRESS syndrome in a 4-year-old child. *Ann Allergy Asthma Immunol* 2016; 116: 366-7.
78. Vasanthan T, Rajaguru G, Venkatesh C, Narayanan P, Gulati R, Toi PC. DRESS Syndrome with peripheral neuropathy due to reactivation of cytomegalovirus in a child. *J Glob Infect Dis* 2015; 7: 89-90.
79. Dilek N, Özkol HU, Akbaş A et al. Cutaneous drug reactions in children: a multicentric study. *Postepy Dermatol Alergol* 2014; 31: 368-71.
80. Teng P, Tan B. Carbamazepine-induced DRESS syndrome in a child: Rapid response to pulsed corticosteroids. *Dermatol Online J* 2013; 19: 18170.
81. Dewan AK, Quinonez RA. Allopurinol-induced DRESS syndrome in an adolescent patient. *Pediatr Dermatol* 2010; 27: 270-3.
82. Tempark T, Satapornpong P, Rerknimitr P et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13:01 allele in the Thai population. *Pharmacogenet Genomics* 2017; 27: 429-37.
83. Rioualen S, Dufau J, Flatres C, Lavenant P, Misery L, Roué JM. DRESS complicated by hemophagocytic lymphohistiocytosis in an infant treated for congenital toxoplasmosis. *Ann Dermatol Venereol* 2017; 144: 784-7.
84. Lavenant P, Roué JM, Huet F, Abasq C, Misery L, Rioualen S. DRESS syndrome and agranulocytosis, a rare combination. *Arch Pediatr* 2017; 24: 752-6.
85. Besli GE, Yildirim S, Yilmaz K, Yuksel E. Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome or hematologic malignancy?: a case report of a 4-year-old boy. *Pediatr Emerg Care* 2017; 33: 494-6.
86. Erdem SB, Nacaroglu HT, Bag O, Karkiner CS, Korkmaz HA, Can D. DRESS syndrome associated with type 2 diabetes in a child. *Cent Eur J Immunol* 2015; 40: 493-6.
87. Avancini J, Maragno L, Santi CG, Criado PR. Drug reaction with eosinophilia and systemic symptoms/drug induced hypersensitivity syndrome: clinical features of 27 patients. *Clin Exp Dermatol* 2015; 40: 851-9.
88. González Díaz C, González Hermosa A, García-Lirio E, Martínez-Aranguren R, Gamboa Setien P. Dress induced by piperacillin-tazobactam in a child. *J Allergy Clin Immunol Pract* 2015; 3: 615-7.
89. Shimabukuro K, Gibbon F, Kerstetter J, Tinsley C, Ashwal S. DRESS associated with perampanel administration in a child with drug-resistant epilepsy. *Neurology* 2014; 83: 2188.
90. Lomairi NE, Abourazzak S, Chaouki S, Atmani S, Hida M. Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) induced by carbamazepine: a case report and literature review. *Pan Afr Med J* 2014; 18: 9.
91. Suthar R, Sankhyan N, Shree H, Singhi P. Reversible Vegetative State in a Child Due to Drug Reaction with Eosinophilia and Systemic Symptoms. *Indian J Pediatr.* 2017; 84: 249-50.
92. Correa-de-Castro B, Paniago AM, Takita LC, Murback ND, Hans-Filho G. Drug reaction with eosinophilia and systemic symptoms: a clinicopathological study of six cases at a teaching hospital in midwestern Brazil. *Int J Dermatol* 2016; 55: 328-34.
93. Ho CH, Uzunyan MY. Myocarditis in drug rash with eosinophilia and systemic symptoms. *Cardiol Young* 2015; 25: 1210-3.
94. Nanishi E, Hoshina T, Ohga S, Nishio H, Hara T. Drug reaction with eosinophilia and systemic symptoms during primary Epstein Barr virus infection. *J Microbiol Immunol Infect* 2015; 48: 109-12.
95. Ramírez A, Abril JC, Cano J. DRESS syndrome due to antibiotic therapy of osteoarticular infections in children: two case reports. *Rev Esp Cir Ortop Traumatol* 2015; 59: 360-4.
96. Cheng J, Rawal S, Roberts A, Guttman OR. Drug reaction with eosinophilia and systemic symptoms syndrome associated with antituberculosis medications. *Pediatr Infect Dis J* 2013; 32: 1388-90.
97. Yusuf IH, Sahare P, Hildebrand GD. DRESS syndrome in a child treated for toxoplasma retinochoroiditis. *J AAPO* 2013; 17: 521-3.
98. Shahbaz S, Sivamani RK, Konia T, Burrall B. A case of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) related to rifinamide. *Dermatol Online J* 2013; 19: 4.
99. Naveen KN, Ravindra MS, Pai VV, Rai V, Athanikar SB, Girish M. Lamotrigine induced DRESS syndrome. *Indian J Pharmacol* 2012; 44: 798-800.
100. Zurina Z, Elizawaty O, Thevarajah S, Norlijah O. Dapsone syndrome—first Malaysian paediatric case report. *Med J Malaysia* 2012; 67: 105-7.
101. Deka NM, Dass R, Das BK, Hoque R. Phenytoin Induced DRESS Syndrome. *Indian J Pediatr* 2013; 80: 266.
102. Buyuktiryaki AB, Bezirganoglu H, Sahiner UM et al. Patch testing is an effective method for the diagnosis of carbamazepine-induced drug reaction, eosinophilia and systemic symptoms (DRESS) syndrome in an 8 year-old girl. *Austral J Dermatol* 2012; 53: 274-7.
103. Bauer KA, Brimhall AK, Chang TT. Drug reaction with eosinophilia and systemic symptoms (DRESS) associated with azithromycin in acute Epstein-Barr virus infection. *Pediatr Dermatol* 2011; 28: 741-3.
104. Orbak Z, Sepetcigil O, Karakelleoğlu C, Gülses S. Penicillin V-induced drug rash with eosinophilia and systemic symptoms. *West Indian Med J* 2010; 59: 722-5.

105. Silva R, Botelho C, Cadinha S, Lisboa C, Azevedo I, Cernadas JR. Possible DRESS syndrome in a child with borreliosis. *Allergol Immunopathol (Madr)*. 2012; 40: 129-31.
106. Hubiche T, Milpied B, Cazeau C, Taïeb A, Léauté-Labrèze C. Association of immunologically confirmed delayed drug reaction and human herpesvirus 6 viremia in a pediatric case of drug-induced hypersensitivity syndrome. *Dermatology* 2011; 222: 140-1.
107. Piñana E, Lei SH, Merino R et al. DRESS-syndrome on sulfasalazine and naproxen treatment for juvenile idiopathic arthritis and reactivation of human herpesvirus 6 in an 11-year old Caucasian boy. *J Clin Pharm Ther* 2010; 35: 365-70.
108. Rosenbaum J, Alex G, Roberts H, Orchard D. Drug rash with eosinophilia and systemic symptoms secondary to sulfasalazine. *J Paediatr Child Health*. 2010; 46: 193-6.
109. Scagni P, Morello M, Ramus MV, Agostini M, Pagliero R. Drug-induced hypersensitivity syndrome associated with Epstein-Barr virus infection: a pediatric case report. *Pediatr Dermatol* 2009; 26: 229-31.
110. Armin S, Chavoshzadeh Z, Mohkam M, Rezaei N. Antiepileptic hypersensitivity and DRESS syndrome due to phenytoin in two pediatric cases. *Turk J Pediatr* 2009; 51: 76-7.
111. Kawakami T, Fujita A, Takeuchi S, Muto S, Soma Y. Drug-induced hypersensitivity syndrome: drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by aspirin treatment of Kawasaki disease. *J Am Acad Dermatol* 2009; 60: 146-9.
112. Seth D, Kamat D, Montejó J. DRESS Syndrome: A Practical Approach for Primary Care Practitioners. *Clin Pediatr (Phila)* 2008; 47: 947-52.
113. Crowell CS, Melin-Aldana H, Tan TQ. Fever, rash, and hepatic dysfunction in a 3-year-old child: a case report. *Clin Pediatr (Phila)* 2008; 47: 517-20.
114. Garnier A, El Marabet el H, Kwon T. Acute renal failure in a 3-year-old child as part of the drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome following hepatitis A. *Pediatr Nephrol* 2008; 23: 667-9.
115. Manuyakorn W, Siripool K, Kamchaisatian W et al. Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children. *Pediatr Allergy Immunol* 2013; 24: 299-303.
116. Ahluwalia J, Abuabara K, Perman MJ, Yan AC. HHV6 involvement in pediatric drug hypersensitivity syndrome. *Br J Dermatol* 2015; 172: 1090-5.
117. Asidharanpillai S, Sabitha S, Riyaz N et al. Drug Reaction with Eosinophilia and Systemic Symptoms in Children: A Prospective Study. *Pediatr Dermatol* 2016; 33: e162-5.
118. Fleming P, Marik PE. The DRESS syndrome: the great clinical mimicker. *Pharmacotherapy* 2011; 31: 332.
119. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part II. Management therapeutics. *J Am Acad Dermatol* 2013; 68: 709.e1-9.
120. Gonçalves MM, Cardoso JC, Gouveia MP et al. Histopathology of the exanthema in DRESS is not specific but may indicate severity of systemic involvement. *Am J Dermatopathol* 2016; 38: 23-33.
121. Skowron F, Bensaid B, Balme B et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): clinicopathological study of 45 cases. *J Eur Acad Dermatol Venereol* 2015; 29: 2199-205.
122. Ogawa K, Morito H, Hasegawa A et al. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS). *J Dermatol Science* 2013; 69: 38-43.
123. Caffarelli C, Franceschini F, Caimmi D, et al. SIAIP position paper: provocation challenge to antibiotics and non-steroidal anti-inflammatory drugs in children. *Ital J Pediatr* 2018; 44: 147.
124. Barbaud A, Collet E, Milpied B, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. *Br J Dermatol* 2013; 168: 555-62.
125. Caglayan Sozmen S, Povesi Dascola C, Gioia E, Mastroilli C, Rizzuti L, Caffarelli C. Diagnostic accuracy of patch test in children with food allergy. *Pediatr Allergy Immunol* 2015; 26: 416-22.
126. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. *Allergy* 2004; 59: 809-20.
127. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. *Allergy* 2007; 62: 1439-44.
128. Jurado-Palomo J, Cabañas R, Prior N, et al. Use of the lymphocyte transformation test in the diagnosis of DRESS syndrome induced by ceftriaxone and piperacillin-tazobactam: two case reports. *J Investig Allergol Clin Immunol* 2010; 20: 433.
129. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. *Br J Dermatol* 2007; 156: 1083-84.
130. Caffarelli C, Cuomo B, Cardinale F, et al. Aetiological factors associated with chronic urticaria in children: a systematic review. *Acta Derm Venereol* 2013; 93: 268-72.
131. Galli E, Neri I, Ricci G, et al. Consensus Conference on Clinical Management of pediatric Atopic Dermatitis. *Ital J Pediatr* 2016; 42: 26.
132. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? *Arch Dermatol* 2000; 136: 323-7.
133. Descamps V, Ranger-Rogez S. DRESS syndrome. *Joint Bone Spine* 2014; 81: 15-21.
134. Natkunarajah J, Goolamali S, Craythorne E et al. Ten cases of drug reaction with eosinophilia and systemic symptoms

- (DRESS) treated with pulsed intravenous methylprednisolone. *Eur J Dermatol* 2011; 21: 385-91.
135. Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. *Dermatology* 2003; 206: 353-6.
136. Ange N, Alley S, Fernando SL, Coyle L, Yun J. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome successfully treated with mepolizumab. *J Allergy Clin Immunol Pract* 2018; 6: 1059-60.
137. Kirchhof MG, Wong A, Dutz JP. Cyclosporine Treatment of Drug-Induced Hypersensitivity Syndrome. *JAMA Dermatol* 2016; 152: 1254-7.
138. Joly P, Janela B, Tetart F, Rogez S, et al. Poor benefit/risk balance of intravenous immunoglobulins in DRESS. *Arch Derm* 2012; 148: 543-4.
139. Moling O, Tappeiner L, Piccin A et al. Treatment of DIHS/DRESS syndrome with combined N-acetylcysteine, prednisone and valganciclovir--a hypothesis. *Med Sci Monit* 2012; 18: CS57-62.
140. Alexander T, Iglesia E, Park Y, et al. Severe DRESS syndrome managed with therapeutic plasma exchange. *Pediatrics* 2013; 131: e945-e949.
141. Zuliani E, Zwahlen H, Gilliet F, Marone C. Vancomycin-induced hypersensitivity reaction with acute renal failure: resolution following cyclosporine treatment. *Clin Nephrol* 2005; 64: 155.
142. De Clercq E. Selective anti-herpesvirus agents. *Antivir Chem Chemother* 2013; 23: 93-101.
143. Caffarelli C, Bernasconi S. Preventing necrotising enterocolitis with probiotics. *Lancet*. 2007; 369: 1578-80.
144. Caffarelli C, Cardinale F, Povesi-Dascola C, Dodi I, Mastrotorilli V, Ricci G. Use of probiotics in pediatric infectious diseases. *Expert Rev Anti Infect Ther* 2015; 13: 1517-35.
145. Picard D, Vellar M, Janela B, Roussel A, Joly P, Musette P. Recurrence of drug-induced reactions in DRESS patients. *J Eur Acad Dermatol Venereol* 2015; 29: 801-4.
146. Aota N, Shiohara T. Viral connection between drug rashes and autoimmune diseases: how autoimmune responses are generated after resolution of drug rashes. *Autoimmun Rev* 2009; 8: 488-94.
147. Ushigome Y, Kano Y, Ishida T, Hirahara K, Shiohara T. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. *J Am Acad Dermatol* 2013; 68: 721-8.
148. Duong TA, Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. *Lancet* 2017; 390: 1996-2011.

Received: 24 January 2019

Accepted: 1 February 2019

Correspondence:

Mori Francesca, M.D.

Allergy Unit, Anna Meyer Children's Hospital,

Department of Pediatrics, University of Florence

Viale Pieraccini, 24 - 50139 Florence, Italy

Tel. +39-055-5662034

Fax +390555662902

E mail: f.mori@meyer.it